http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 08 Oct 2026 09:53:14 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html <p>Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.</p> <p>The ranking represents current favorite stock ideas from Raymond James equity research analysts, with each analyst selecting one buy-rated idea from their coverage universe. The list includes companies rated either Strong Buy or Outperform. </p> <p><strong>1. Dyne Therapeutics</strong> - Raymond James ranks <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Dyne</span></span> Therapeutics as its top healthcare pick ahead of anticipated results from the z-rostudirsen (DYNE-251) http://www.streetinsider.com/Investing/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html Thu, 08 Oct 2026 09:53:14 -0400 DYN OCUL TRVI http://www.streetinsider.com/General+News/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html <p>Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.</p> <p>The ranking represents current favorite stock ideas from Raymond James equity research analysts, with each analyst selecting one buy-rated idea from their coverage universe. The list includes companies rated either Strong Buy or Outperform. </p> <p><strong>1. Dyne Therapeutics</strong> - Raymond James ranks <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Dyne</span></span> Therapeutics as its top healthcare pick ahead of anticipated results from the z-rostudirsen (DYNE-251) http://www.streetinsider.com/General+News/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html Thu, 08 Oct 2026 09:53:14 -0400 DYN OCUL TRVI http://www.streetinsider.com/Investing/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html <p>Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.</p> <p>The ranking represents current favorite stock ideas from Raymond James equity research analysts, with each analyst selecting one buy-rated idea from their coverage universe. The list includes companies rated either Strong Buy or Outperform. </p> <p><strong>1. Dyne Therapeutics</strong> - Raymond James ranks <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Dyne</span></span> Therapeutics as its top healthcare pick ahead of anticipated results from the z-rostudirsen (DYNE-251) http://www.streetinsider.com/Investing/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html Thu, 08 Oct 2026 09:53:14 -0400 DYN OCUL TRVI http://www.streetinsider.com/General+News/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html <p>Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.</p> <p>The ranking represents current favorite stock ideas from Raymond James equity research analysts, with each analyst selecting one buy-rated idea from their coverage universe. The list includes companies rated either Strong Buy or Outperform. </p> <p><strong>1. Dyne Therapeutics</strong> - Raymond James ranks <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Dyne</span></span> Therapeutics as its top healthcare pick ahead of anticipated results from the z-rostudirsen (DYNE-251) http://www.streetinsider.com/General+News/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html Thu, 08 Oct 2026 09:53:14 -0400 DYN OCUL TRVI http://www.streetinsider.com/Investing/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html <p>Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.</p> <p>The ranking represents current favorite stock ideas from Raymond James equity research analysts, with each analyst selecting one buy-rated idea from their coverage universe. The list includes companies rated either Strong Buy or Outperform. </p> <p><strong>1. Dyne Therapeutics</strong> - Raymond James ranks <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Dyne</span></span> Therapeutics as its top healthcare pick ahead of anticipated results from the z-rostudirsen (DYNE-251) http://www.streetinsider.com/Investing/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html Thu, 08 Oct 2026 09:53:14 -0400 DYN OCUL TRVI http://www.streetinsider.com/General+News/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html <p>Investing.com -- Raymond James has identified its top stock picks in the healthcare sector, highlighting companies with upcoming clinical trial results and promising drug development programs. The firm’s Analyst Current Favorites list features biotechnology companies positioned for potential catalysts in 2025 and 2026.</p> <p>The ranking represents current favorite stock ideas from Raymond James equity research analysts, with each analyst selecting one buy-rated idea from their coverage universe. The list includes companies rated either Strong Buy or Outperform. </p> <p><strong>1. Dyne Therapeutics</strong> - Raymond James ranks <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Dyne</span></span> Therapeutics as its top healthcare pick ahead of anticipated results from the z-rostudirsen (DYNE-251) http://www.streetinsider.com/General+News/Top+4+Healthcare+Stocks+Backed+by+Raymond+James+Analysts/27165068.html Thu, 08 Oct 2026 09:53:14 -0400 DYN OCUL TRVI http://www.streetinsider.com/Analyst+Comments/Dyne+Therapeutics+%28DYN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/27163516.html <p>Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Dyne Therapeutics (NASDAQ: DYN).</p><p>The analyst commented, "We value DYN shares based on a risk-adjusted DCF analysis of z-rostudirsen (DMD51) and zbasivarsen (DM1), and ascribe modest value ($500M) to the FORCE platform. Our model assumes a 12% discount rate and 5% terminal growth rate. Risks. Platform safety/translation risk. All of DYN's key programs are derived from the FORCE platform. FORCE and other muscle delivery approaches have encountered rare safety events in the past. Any future adverse events could be damaging. Ex-U.S. regulatory risks in DMD exon 51. The EMA is likely http://www.streetinsider.com/Analyst+Comments/Dyne+Therapeutics+%28DYN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/27163516.html Thu, 08 Oct 2026 07:08:25 -0400 DYN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dyne+Therapeutics%2C+Inc.+++For%3A+Oct+02++Filed+by%3A+Posner+Brian+S/27155679.html si-local-file:///var/storage/secattach/20261006/27155679.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Dyne+Therapeutics%2C+Inc.+++For%3A+Oct+02++Filed+by%3A+Posner+Brian+S/27155679.html Tue, 06 Oct 2026 16:15:00 -0400 DYN http://www.streetinsider.com/Options/Increasing+unusual+call+option+volume%3A+GFL+DYN+SDGR+QSR+QSI+HBAN+ITB+BIRK+PACB/27138647.html <p>Increasing unusual call option volume: GFL DYN SDGR QSR QSI HBAN ITB BIRK PACB</p> http://www.streetinsider.com/Options/Increasing+unusual+call+option+volume%3A+GFL+DYN+SDGR+QSR+QSI+HBAN+ITB+BIRK+PACB/27138647.html Fri, 02 Oct 2026 06:16:21 -0400 DYN http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Dyne+Therapeutics+%28DYN%29/27126698.html <p>Stifel analyst Paul Matteis reiterated a Buy rating and $37.00 price target on Dyne Therapeutics (NASDAQ: DYN).</p><p>The analyst commented, "We're reiterating our Buy Rating on DYN, following additional analyses presented at WMS/AANEM comparing pooled patients from their ph1/2 to matched DM1 external controls from the END-DM1 NH study. Results showed consistent favorable benefits across various functional endpoints at 12 months follow-up, which are encouraging. Meanwhile, DYN also disclosed vHOT baselines for the REC study, which were largely in-line with the ph1/2. We caught up with mgmt who were satisfied with were the REC baselines landed, and continue to reiterate their http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Dyne+Therapeutics+%28DYN%29/27126698.html Wed, 30 Sep 2026 10:00:03 -0400 DYN http://www.streetinsider.com/Analyst+PT+Change/Dyne+Therapeutics+%28DYN%29+PT+Lowered+to+%2432+at+H.C.+Wainwright/27125186.html (Updated - September 30, 2026 7:14 AM EDT) <p>H.C. Wainwright analyst Andrew Fein lowered the price target on Dyne Therapeutics (NASDAQ: DYN) to $32.00 (from $50.00) while maintaining a Buy rating.</p><p>The analyst commented: "Yesterday, Dyne shared additional one-year data from a pooled MAD cohort (N=25–26) of ACHIEVE, ahead of the 1Q 2027 REC readout. The results included a 3.6 sec relative vHOT improvement over placebo at 6 months, sustained 12-month functional improvement across 5xSTS, 10MWR, QMT, and MDHI (with movement across six CNS subscales), and a REC baseline vHOT of 8.3 sec that essentially matches the MAD baseline of 8.2 sec. http://www.streetinsider.com/Analyst+PT+Change/Dyne+Therapeutics+%28DYN%29+PT+Lowered+to+%2432+at+H.C.+Wainwright/27125186.html Wed, 30 Sep 2026 07:14:53 -0400 DYN http://www.streetinsider.com/Analyst+Comments/Dyne+Therapeutics+%28DYN%29+PT+Lowered+to+%2432+at+H.C.+Wainwright/27125186.html (Updated - September 30, 2026 7:14 AM EDT) <p>H.C. Wainwright analyst Andrew Fein lowered the price target on Dyne Therapeutics (NASDAQ: DYN) to $32.00 (from $50.00) while maintaining a Buy rating.</p><p>The analyst commented: "Yesterday, Dyne shared additional one-year data from a pooled MAD cohort (N=25–26) of ACHIEVE, ahead of the 1Q 2027 REC readout. The results included a 3.6 sec relative vHOT improvement over placebo at 6 months, sustained 12-month functional improvement across 5xSTS, 10MWR, QMT, and MDHI (with movement across six CNS subscales), and a REC baseline vHOT of 8.3 sec that essentially matches the MAD baseline of 8.2 sec. http://www.streetinsider.com/Analyst+Comments/Dyne+Therapeutics+%28DYN%29+PT+Lowered+to+%2432+at+H.C.+Wainwright/27125186.html Wed, 30 Sep 2026 07:14:53 -0400 DYN http://www.streetinsider.com/Analyst+Comments/Dyne+Therapeutics+%28DYN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+on+Ph12+Data+Release/27125073.html <p>Cantor Fitzgerald analyst Eric Schmidt reiterated an Overweight rating on Dyne Therapeutics (NASDAQ: DYN).</p><p>The analyst commented, "Dyne released additional 1-year data from its Phase 1/2 ACHIEVE study of z-basivarsen in DM1 today. The results are being presented at this week’s WMS and AANEM meetings. Recall, z-basivarsen is being evaluated in an N=71 registrational expansion cohort (REC) that is expected to read out in 1Q27, with vHOT (video hand opening time) at 6 months as the primary endpoint. This study could support an accelerated approval filing in 3Q27. This trial has come under scrutiny following NVS’ (NC) announcement that its Phase http://www.streetinsider.com/Analyst+Comments/Dyne+Therapeutics+%28DYN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+on+Ph12+Data+Release/27125073.html Wed, 30 Sep 2026 07:00:20 -0400 DYN http://www.streetinsider.com/Analyst+Comments/Jefferies+Reiterates+Buy+Rating+on+Dyne+Therapeutics+%28DYN%29/27124406.html <p>Jefferies analyst Andrew Tsai reiterated a Buy rating and $50.00 price target on Dyne Therapeutics (NASDAQ: DYN).</p><p>The analyst comments "At WMS 2026, mgmt shared baseline vHOT values for z-basivarsen's (ASO) fully enrolled pivotal Phase II study, whose DM1 data in Q1:27 could support an accelerated approval (AA) filing in Q3:27 ($3B+ opportunity). In short, the Phase II baseline vHOT is similar to the prior (+) Phase I/II, maximizing the likelihood that vHOT hits stat-sig (primary endpoint). Moreover, LT Phase I/II data (vs natural history) signals meaningful efficacy (i.e., a real drug effect)."</p><p>For an analyst ratings summary and ratings history on http://www.streetinsider.com/Analyst+Comments/Jefferies+Reiterates+Buy+Rating+on+Dyne+Therapeutics+%28DYN%29/27124406.html Wed, 30 Sep 2026 05:43:25 -0400 DYN http://www.streetinsider.com/Investing/Dyne+Therapeutics+stock+rises+on+positive+DM1+trial+results/27123201.html <p>Investing.com -- <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Dyne</span></span> Therapeutics Inc (NASDAQ:DYN) shares gained 2.1% in after-hours trading Tuesday following the release of one-year trial data for its experimental DM1 treatment z-basivarsen.</p> <p>The clinical-stage biotechnology company reported functional improvement data from the multiple ascending dose portion of its Phase 1/2 ACHIEVE trial, showing positive results across multiple measures at 12 months.</p> <div id="message-list_1790278101.205999" aria-setsize="-1"> <div> <div aria-roledescription="message"> <div> <div> <div> <div> <div> <div> <div draggable="false"> <div> <div> </div> <div> The pooled dose group of 25-26 participants demonstrated a mean decrease of 3.2 seconds in video hand opening time at 6 months from a baseline of 8.2 seconds, compared to an increase of 0.4 seconds in the placebo group, representing http://www.streetinsider.com/Investing/Dyne+Therapeutics+stock+rises+on+positive+DM1+trial+results/27123201.html Tue, 29 Sep 2026 16:54:30 -0400 DYN http://www.streetinsider.com/General+News/Dyne+Therapeutics+stock+rises+on+positive+DM1+trial+results/27123201.html <p>Investing.com -- <span itemscope="" itemtype="http://schema.org/Corporation"><span itemprop="name">Dyne</span></span> Therapeutics Inc (NASDAQ:DYN) shares gained 2.1% in after-hours trading Tuesday following the release of one-year trial data for its experimental DM1 treatment z-basivarsen.</p> <p>The clinical-stage biotechnology company reported functional improvement data from the multiple ascending dose portion of its Phase 1/2 ACHIEVE trial, showing positive results across multiple measures at 12 months.</p> <div id="message-list_1790278101.205999" aria-setsize="-1"> <div> <div aria-roledescription="message"> <div> <div> <div> <div> <div> <div> <div draggable="false"> <div> <div> </div> <div> The pooled dose group of 25-26 participants demonstrated a mean decrease of 3.2 seconds in video hand opening time at 6 months from a baseline of 8.2 seconds, compared to an increase of 0.4 seconds in the placebo group, representing http://www.streetinsider.com/General+News/Dyne+Therapeutics+stock+rises+on+positive+DM1+trial+results/27123201.html Tue, 29 Sep 2026 16:54:30 -0400 DYN http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Dyne+Therapeutics%2C+Inc.+++For%3A+Sep+29/27122596.html si-local-file:///var/storage/secattach/20260929/27122596.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Dyne+Therapeutics%2C+Inc.+++For%3A+Sep+29/27122596.html Tue, 29 Sep 2026 16:10:00 -0400 DYN http://www.streetinsider.com/FDA/Dyne+Therapeutics+reports+one-year+DM1+trial+data+for+z-basivarsen/27122427.html <p>Dyne Therapeutics (Nasdaq: DYN) released one-year efficacy data from the multiple ascending dose portion of its Phase 1/2 ACHIEVE clinical trial evaluating z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1), according to a company statement. The data were presented at the 31st Annual International Congress of the World Muscle Society and the 2026 Annual Meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine.</p> <p>The analysis pooled participants (N=25-26) across three dose cohorts: 3.4 mg/kg every four weeks, 5.4 mg/kg every eight weeks, and 6.8 mg/kg every eight weeks. At 12 months, results were compared against a propensity-matched natural history cohort http://www.streetinsider.com/FDA/Dyne+Therapeutics+reports+one-year+DM1+trial+data+for+z-basivarsen/27122427.html Tue, 29 Sep 2026 16:05:18 -0400 DYN http://www.streetinsider.com/Press+Releases/Dyne+Therapeutics+Announces+Additional+One-Year+Clinical+Data+from+Phase+12+ACHIEVE+Trial+of+Z-Basivarsen+%28DYNE-101%29+for+Myotonic+Dystrophy+Type+1+%28DM1%29/27122407.html <p align="center"><em>- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months -</em></p> <p align="center"><em>- Data continued to support improvement at 6 months in video hand opening time (vHOT) as an early indicator of clinical benefit with z-basivarsen in DM1 -</em></p> <p align="center"><em>- Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC), with a primary endpoint of change from baseline in vHOT http://www.streetinsider.com/Press+Releases/Dyne+Therapeutics+Announces+Additional+One-Year+Clinical+Data+from+Phase+12+ACHIEVE+Trial+of+Z-Basivarsen+%28DYNE-101%29+for+Myotonic+Dystrophy+Type+1+%28DM1%29/27122407.html Tue, 29 Sep 2026 16:05:00 -0400 DYN http://www.streetinsider.com/Globe+Newswire/Dyne+Therapeutics+Announces+Additional+One-Year+Clinical+Data+from+Phase+12+ACHIEVE+Trial+of+Z-Basivarsen+%28DYNE-101%29+for+Myotonic+Dystrophy+Type+1+%28DM1%29/27122407.html <p align="center"><em>- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus a matched natural history cohort across multiple measures at 12 months -</em></p> <p align="center"><em>- Data continued to support improvement at 6 months in video hand opening time (vHOT) as an early indicator of clinical benefit with z-basivarsen in DM1 -</em></p> <p align="center"><em>- Dyne continues to expect topline data in Q1 2027 from the ACHIEVE registrational expansion cohort (REC), with a primary endpoint of change from baseline in vHOT http://www.streetinsider.com/Globe+Newswire/Dyne+Therapeutics+Announces+Additional+One-Year+Clinical+Data+from+Phase+12+ACHIEVE+Trial+of+Z-Basivarsen+%28DYNE-101%29+for+Myotonic+Dystrophy+Type+1+%28DM1%29/27122407.html Tue, 29 Sep 2026 16:05:00 -0400 DYN http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+Reiterates+Overweight+Rating+on+Dyne+Therapeutics+%28DYN%29/27118897.html <p>Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $47.00 price target on Dyne Therapeutics (NASDAQ: DYN).</p><p>The analyst commented: "Confident in Accelerated Approval for Z-ros by January 21st PDUFA Date; We are confident Zeleciment rostudirsen (z-ros) will gain accelerated approval in DMD boys amenable to exon 51 skipping by the January 21st PDUFA date with blockbuster potential. 20mg/kg monthly z-ros showed statistically significant increases in dystrophin expression and function endpoints time to rise (TTR) and 10-meter walk/run velocity. The confirmatory Phase III FORZETTO trial of z-ros in 90 DMD-51 boys is underway and Dyne is developing FORCE candidates for http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+Reiterates+Overweight+Rating+on+Dyne+Therapeutics+%28DYN%29/27118897.html Tue, 29 Sep 2026 09:25:05 -0400 DYN http://www.streetinsider.com/Press+Releases/Dyne+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27075780.html <p align="left">WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=liurwS_Y9S46LmIichDUFNIRC1he6jhCHzqHEPH2rezQJsJ1vfDebynXDo5QTwsFzScCjw5dAn8DOOuY3oS4WSfoF7oKTc7LMpo8jxnyFSw=" rel="nofollow" target="_blank">Dyne Therapeutics, Inc</a>. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 278,100 shares of Dyne’s common stock at a per http://www.streetinsider.com/Press+Releases/Dyne+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27075780.html Thu, 17 Sep 2026 16:05:00 -0400 DYN http://www.streetinsider.com/Globe+Newswire/Dyne+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27075780.html <p align="left">WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=liurwS_Y9S46LmIichDUFNIRC1he6jhCHzqHEPH2rezQJsJ1vfDebynXDo5QTwsFzScCjw5dAn8DOOuY3oS4WSfoF7oKTc7LMpo8jxnyFSw=" rel="nofollow" target="_blank">Dyne Therapeutics, Inc</a>. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).</p> <p>The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 278,100 shares of Dyne’s common stock at a per http://www.streetinsider.com/Globe+Newswire/Dyne+Therapeutics+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27075780.html Thu, 17 Sep 2026 16:05:00 -0400 DYN http://www.streetinsider.com/Analyst+PT+Change/Dyne+Therapeutics+%28DYN%29+PT+Lowered+to+%2436+at+Morgan+Stanley/27039405.html Morgan Stanley analyst Michael E Ulz lowered the price target on Dyne Therapeutics (NASDAQ: DYN) to $36.00 (from $45.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Dyne+Therapeutics+%28DYN%29+PT+Lowered+to+%2436+at+Morgan+Stanley/27039405.html Wed, 09 Sep 2026 07:54:17 -0400 DYN http://www.streetinsider.com/Analyst+PT+Change/Dyne+Therapeutics+%28DYN%29+PT+Lowered+to+%2430+at+RBC+Capital+Following+NVS+Setback/27039236.html (Updated - September 9, 2026 7:53 AM EDT) <p>RBC Capital analyst Luca Issi lowered the price target on Dyne Therapeutics (NASDAQ: DYN) to $30.00 (from $35.00) while maintaining an Outperform rating.</p><p>The analyst commented: 'NVS Setback Unfortunate But We Don't Think Thesis Changing; NVS announced earlier today that their pivotal Phase III trial missed the primary endpoint (see here for our first take) and we just had an opportunity to catch up with the DYN C-suite. The team highlights that they were surprised by the miss, but they also note some key differences around transferrin targeting (full length antibody vs antibody http://www.streetinsider.com/Analyst+PT+Change/Dyne+Therapeutics+%28DYN%29+PT+Lowered+to+%2430+at+RBC+Capital+Following+NVS+Setback/27039236.html Wed, 09 Sep 2026 07:53:15 -0400 DYN